BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 15050465)

  • 21. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial.
    Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L
    Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF).
    Pandian Z; McTavish AR; Aucott L; Hamilton MP; Bhattacharya S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD004379. PubMed ID: 20091563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial.
    Lainas TG; Sfontouris IA; Papanikolaou EG; Zorzovilis JZ; Petsas GK; Lainas GT; Kolibianakis EM
    Hum Reprod; 2008 Jun; 23(6):1355-8. PubMed ID: 18403419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of mild and microdose GnRH agonist flare protocols on IVF outcome in poor responders.
    Karimzadeh MA; Mashayekhy M; Mohammadian F; Moghaddam FM
    Arch Gynecol Obstet; 2011 May; 283(5):1159-64. PubMed ID: 21221982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial.
    Maged AM; Nada AM; Abohamila F; Hashem AT; Mostafa WA; Elzayat AR
    Reprod Sci; 2015 Dec; 22(12):1627-31. PubMed ID: 26045549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered vascular endothelial growth factor expression during GnRH antagonist protocol in women of reproductive age with normal baseline hormone profiles.
    Koo YA; Lee B; Park HJ; Choi J; Lee E; Choi D
    Fertil Steril; 2009 Mar; 91(3):744-8. PubMed ID: 18321491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
    Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
    Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist "flare-up" versus antagonist in the management of poor responders undergoing in vitro fertilization treatment.
    Mohamed KA; Davies WA; Allsopp J; Lashen H
    Fertil Steril; 2005 Feb; 83(2):331-5. PubMed ID: 15705370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise.
    Friis Wang N; Skouby SO; Humaidan P; Andersen CY
    Hum Reprod; 2019 May; 34(5):942-948. PubMed ID: 30927415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
    Maheshwari A; Gibreel A; Siristatidis CS; Bhattacharya S
    Cochrane Database Syst Rev; 2011 Aug; (8):CD006919. PubMed ID: 21833958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
    DiLuigi AJ; Engmann L; Schmidt DW; Benadiva CA; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2531-3. PubMed ID: 21324455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corifollitropin alfa followed by hpHMG in GnRH agonist protocols. Two prospective feasibility studies in poor ovarian responders.
    Polyzos NP; Corona R; Van De Vijver A; Blockeel C; Drakopoulos P; Vloeberghs V; De Vos M; Camus M; Humaidan P; Tournaye H
    Gynecol Endocrinol; 2015; 31(11):885-90. PubMed ID: 26172925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.